This trial will test the safety and effectiveness of a new imaging agent, [18F]UCB-2897, in people with Parkinson's disease or Multiple System Atrophy. The goal is to see if the agent can produce a specific signal in the brain related to alpha-synuclein, a protein involved in these diseases.
- Multi-System Atrophy
- Parkinson's Disease
- Healthy Subjects
3 Primary · 0 Secondary · Reporting Duration: [18F]UCB-2897 PET Imaging Visit
Awards & Highlights
1 Treatment Group
1 of 1
14 Total Participants · 1 Treatment Group
Primary Treatment: [18F]UCB-2897 · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent is the participant pool of this research project expanding?
"That is accurate. According to the information on clinicaltrials.gov, this medical trial was initially posted on January 31st 2022 and last modified on March 1st 2022. Currently, there are 14 patients needed across one single site for the study's completion." - Anonymous Online Contributor
Are there any current opportunities to join this experiment?
"According to the records hosted on clinicaltrials.gov, this trial is searching for participants; it was published at the beginning of January 2021 and underwent its most recent update in March 2022." - Anonymous Online Contributor
What are the potential hazards associated with administering [18F]UCB-2897?
"Due to the limited data available, [18F]UCB-2897 was assigned a score of 1 in terms of safety on our team's scale. This is because this trial only reaches Phase 1 status and there is restricted information confirming efficacy or security." - Anonymous Online Contributor